Logo image of EVAX

EVAXION A/S (EVAX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:EVAX - US29970R3030 - ADR

5.935 USD
+0.28 (+5.04%)
Last: 11/28/2025, 8:26:20 PM
Fundamental Rating

2

EVAX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. EVAX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EVAX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EVAX had negative earnings in the past year.
In the past year EVAX has reported a negative cash flow from operations.
EVAX had negative earnings in each of the past 5 years.
EVAX had a negative operating cash flow in each of the past 5 years.
EVAX Yearly Net Income VS EBIT VS OCF VS FCFEVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

EVAX's Return On Assets of -53.35% is in line compared to the rest of the industry. EVAX outperforms 46.72% of its industry peers.
EVAX has a Return On Equity of -192.35%. This is in the lower half of the industry: EVAX underperforms 66.04% of its industry peers.
Industry RankSector Rank
ROA -53.35%
ROE -192.35%
ROIC N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVAX Yearly ROA, ROE, ROICEVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

EVAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVAX Yearly Profit, Operating, Gross MarginsEVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

4

2. Health

2.1 Basic Checks

EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVAX has more shares outstanding
Compared to 5 years ago, EVAX has less shares outstanding
EVAX has a better debt/assets ratio than last year.
EVAX Yearly Shares OutstandingEVAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EVAX Yearly Total Debt VS Total AssetsEVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

EVAX has an Altman-Z score of 0.08. This is a bad value and indicates that EVAX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.08, EVAX is in the better half of the industry, outperforming 61.35% of the companies in the same industry.
A Debt/Equity ratio of 1.73 is on the high side and indicates that EVAX has dependencies on debt financing.
EVAX has a Debt to Equity ratio of 1.73. This is in the lower half of the industry: EVAX underperforms 79.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACC5.77%
EVAX Yearly LT Debt VS Equity VS FCFEVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

EVAX has a Current Ratio of 3.42. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.
EVAX has a Current ratio of 3.42. This is comparable to the rest of the industry: EVAX outperforms 40.90% of its industry peers.
A Quick Ratio of 3.42 indicates that EVAX has no problem at all paying its short term obligations.
The Quick ratio of EVAX (3.42) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 3.42
EVAX Yearly Current Assets VS Current LiabilitesEVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

EVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.07%, which is quite impressive.
EVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 132.20%.
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105%
Revenue 1Y (TTM)132.2%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%148.33%

3.2 Future

EVAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.04% yearly.
The Revenue is expected to grow by 40.90% on average over the next years. This is a very strong growth
EPS Next Y21.68%
EPS Next 2Y14.6%
EPS Next 3Y92.2%
EPS Next 5Y15.04%
Revenue Next Year14.94%
Revenue Next 2Y-2.04%
Revenue Next 3Y73.05%
Revenue Next 5Y40.9%

3.3 Evolution

EVAX Yearly Revenue VS EstimatesEVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M 40M
EVAX Yearly EPS VS EstimatesEVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVAX. In the last year negative earnings were reported.
Also next year EVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVAX Price Earnings VS Forward Price EarningsEVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVAX Per share dataEVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as EVAX's earnings are expected to grow with 92.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.6%
EPS Next 3Y92.2%

More info and screens

0

5. Dividend

5.1 Amount

EVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVAXION A/S

NASDAQ:EVAX (11/28/2025, 8:26:20 PM)

5.935

+0.28 (+5.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-05 2026-03-05/amc
Inst Owners1.91%
Inst Owner Change-2.67%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap47.03M
Revenue(TTM)7.65M
Net Income(TTM)-11.98M
Analysts82.5
Price Target12.58 (111.96%)
Short Float %1.89%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.81%
Min EPS beat(2)24.59%
Max EPS beat(2)97.03%
EPS beat(4)4
Avg EPS beat(4)54.87%
Min EPS beat(4)11.56%
Max EPS beat(4)97.03%
EPS beat(8)7
Avg EPS beat(8)54.84%
EPS beat(12)10
Avg EPS beat(12)37.39%
EPS beat(16)13
Avg EPS beat(16)31.2%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.12%
PT rev (3m)105.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)158.82%
EPS NY rev (1m)-2.38%
EPS NY rev (3m)3.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.81
P/FCF N/A
P/OCF N/A
P/B 7.55
P/tB 7.55
EV/EBITDA N/A
EPS(TTM)-4.01
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.4
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.35%
ROE -192.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.5%
ROA(5y)-109.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 3.42
Altman-Z 0.08
F-Score6
WACC5.77%
ROIC/WACCN/A
Cap/Depr(3y)21.76%
Cap/Depr(5y)127.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105%
EPS Next Y21.68%
EPS Next 2Y14.6%
EPS Next 3Y92.2%
EPS Next 5Y15.04%
Revenue 1Y (TTM)132.2%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%148.33%
Revenue Next Year14.94%
Revenue Next 2Y-2.04%
Revenue Next 3Y73.05%
Revenue Next 5Y40.9%
EBIT growth 1Y26.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.7%
OCF growth 3YN/A
OCF growth 5YN/A

EVAXION A/S / EVAX FAQ

Can you provide the ChartMill fundamental rating for EVAXION A/S?

ChartMill assigns a fundamental rating of 2 / 10 to EVAX.


What is the valuation status of EVAXION A/S (EVAX) stock?

ChartMill assigns a valuation rating of 1 / 10 to EVAXION A/S (EVAX). This can be considered as Overvalued.


Can you provide the profitability details for EVAXION A/S?

EVAXION A/S (EVAX) has a profitability rating of 0 / 10.


How financially healthy is EVAXION A/S?

The financial health rating of EVAXION A/S (EVAX) is 4 / 10.


What is the earnings growth outlook for EVAXION A/S?

The Earnings per Share (EPS) of EVAXION A/S (EVAX) is expected to grow by 21.68% in the next year.